Atossa Therapeutics, Inc. (NASDAQ:ATOS) Stock Position Reduced by MetLife Investment Management LLC

MetLife Investment Management LLC lessened its position in shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS) by 28.2% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 23,978 shares of the company’s stock after selling 9,427 shares during the period. MetLife Investment Management LLC’s holdings in Atossa Therapeutics were worth $36,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the company. The Manufacturers Life Insurance Company acquired a new stake in shares of Atossa Therapeutics during the 3rd quarter worth approximately $75,000. Intech Investment Management LLC acquired a new stake in shares of Atossa Therapeutics during the 3rd quarter worth approximately $29,000. SG Americas Securities LLC raised its position in shares of Atossa Therapeutics by 254.3% during the 3rd quarter. SG Americas Securities LLC now owns 41,849 shares of the company’s stock worth $64,000 after purchasing an additional 30,037 shares during the period. XTX Topco Ltd acquired a new stake in shares of Atossa Therapeutics during the 2nd quarter worth approximately $29,000. Finally, Renaissance Technologies LLC raised its position in shares of Atossa Therapeutics by 11.9% during the 2nd quarter. Renaissance Technologies LLC now owns 1,550,910 shares of the company’s stock worth $1,846,000 after purchasing an additional 164,540 shares during the period. Institutional investors own 12.74% of the company’s stock.

Atossa Therapeutics Price Performance

ATOS opened at $1.26 on Wednesday. Atossa Therapeutics, Inc. has a 12 month low of $0.70 and a 12 month high of $2.31. The stock has a market cap of $158.51 million, a P/E ratio of -5.73 and a beta of 1.22. The stock’s 50 day moving average price is $1.37 and its 200 day moving average price is $1.33.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. StockNews.com cut Atossa Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, November 18th. Ascendiant Capital Markets increased their price target on Atossa Therapeutics from $6.50 to $7.00 and gave the stock a “buy” rating in a research report on Monday. Finally, HC Wainwright raised their target price on Atossa Therapeutics from $6.00 to $7.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.